Cr Pharmaceutical
Cr Pharmaceutical, officially known as China Resources Pharmaceutical Group Limited, is a leading player in the pharmaceutical industry, headquartered in Hong Kong. Established in 1992, the company has grown significantly, with a strong presence in major operational regions across China and beyond. Specialising in the research, development, manufacturing, and distribution of a wide range of pharmaceutical products, Cr Pharmaceutical is renowned for its commitment to quality and innovation. Its core offerings include prescription medications, over-the-counter drugs, and healthcare products, all designed to meet the diverse needs of patients and healthcare providers. With a robust market position, Cr Pharmaceutical has achieved notable milestones, including strategic partnerships and expansions that enhance its competitive edge. The company continues to focus on advancing healthcare solutions, solidifying its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Cr Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cr Pharmaceutical's score of 41 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cr Pharmaceutical's reported carbon emissions
In 2023, Cr Pharmaceutical reported total carbon emissions of approximately 725,648,620 kg CO2e, with Scope 1 emissions at about 170,536,140 kg CO2e and Scope 2 emissions at approximately 555,112,180 kg CO2e. This represents a decrease from 2022, where total emissions were about 774,980,600 kg CO2e, with Scope 1 at approximately 160,986,950 kg CO2e, Scope 2 at about 613,993,650 kg CO2e, and Scope 3 emissions at approximately 90,182,330 kg CO2e. Cr Pharmaceutical has set ambitious reduction targets as part of its long-term climate commitments. By the end of the 14th Five-Year Plan period in 2025, the company aims to reduce carbon dioxide emission intensity by 10% compared to the 2020 baseline of 0.3184 tonnes/RMB 10,000. Additionally, they plan to decrease comprehensive energy consumption per RMB 10,000 of added value by 8% for Scope 1 emissions and by an average annual decrease of 2.7% for Scope 2 emissions from 2021 to 2030. These initiatives reflect Cr Pharmaceutical's commitment to sustainability and reducing its carbon footprint, aligning with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 00,000 | 00,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 0,000,000 | 0,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cr Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
